Published in BMC Infect Dis on March 05, 2013
Scoping the impact of changes in population age-structure on the future burden of foodborne disease in the Netherlands, 2020-2060. Int J Environ Res Public Health (2013) 0.78
On the use of matrices in certain population mathematics. Biometrika (1945) 5.07
Hepatitis A. Lancet (1998) 2.35
Effect of hepatitis A vaccination programs for migrant children on the incidence of hepatitis A in The Netherlands. Eur J Public Health (2009) 2.32
Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol (2012) 2.01
[Surveillance of hepatitis A in the Netherlands 1993-2002]. Ned Tijdschr Geneeskd (2004) 1.42
Antibody against hepatitis A in seven European countries. II. Statistical analysis of cross-sectional surveys. Am J Epidemiol (1979) 1.35
Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect (1998) 1.34
Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics (2002) 1.30
New methodology for estimating the burden of infectious diseases in Europe. PLoS Med (2012) 1.21
The burden of infectious diseases in Europe: a pilot study. Euro Surveill (2007) 1.18
Fecal-orally transmitted diseases among travelers are decreasing due to better hygienic standards at travel destination. J Travel Med (2010) 1.00
The prevalence of antibodies to hepatitis A virus and its determinants in The Netherlands: a population-based survey. Epidemiol Infect (2000) 0.99
Cost-utility of universal hepatitis A vaccination in Canada. Vaccine (2007) 0.98
The impact of demographic change on the estimated future burden of infectious diseases: examples from hepatitis B and seasonal influenza in the Netherlands. BMC Public Health (2012) 0.94
The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adolesc Med (2000) 0.93
Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995-1996 and 2006-2007. Epidemiol Infect (2011) 0.88
Hepatitis A in the United States. Pediatr Infect Dis J (2004) 0.87
Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the western United States. Infect Control Hosp Epidemiol (2004) 0.86
A dynamic model for assessing universal Hepatitis A vaccination in Canada. Vaccine (2006) 0.84
Outbreak of hepatitis A in Rotterdam associated with visits to 'darkrooms' in gay bars. Commun Dis Public Health (1999) 0.83
Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A. BMC Infect Dis (2006) 0.83
Relationship between prevalence of antibody to hepatitis A antigen and age: a cohort effect? J Infect Dis (1978) 0.83
Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J (2002) 0.81
[The epidemiology of hepatitis A in the Netherlands, 1957-1998]. Ned Tijdschr Geneeskd (1998) 0.78
Assessing potential introduction of universal or targeted hepatitis A vaccination in the Netherlands. Vaccine (2012) 0.78
Disease burden of foodborne pathogens in the Netherlands, 2009. Int J Food Microbiol (2012) 2.01
The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine (2009) 1.94
Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81
Estimating the transfusion transmission risk of Q fever. Transfusion (2014) 1.42
New methodology for estimating the burden of infectious diseases in Europe. PLoS Med (2012) 1.21
The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseases. PLoS One (2013) 1.17
Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. BMC Public Health (2014) 1.17
High infectivity and pathogenicity of influenza A virus via aerosol and droplet transmission. Epidemics (2010) 1.09
Elimination of HIV by test and treat: a phantom of wishful thinking? AIDS (2012) 0.98
Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr (2013) 0.96
An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe". Vaccine (2010) 0.94
Analysis of timeliness of infectious disease reporting in the Netherlands. BMC Public Health (2011) 0.93
Usefulness of primary care electronic networks to assess the incidence of chlamydia, diagnosed by general practitioners. BMC Fam Pract (2011) 0.86
Human dose response relation for airborne exposure to Coxiella burnetii. BMC Infect Dis (2013) 0.86
Third Italian national survey on knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health education campaigns. Eur J Public Health (2006) 0.83
Modeling the transmission risk of emerging infectious diseases through blood transfusion. Transfusion (2012) 0.83
Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Med (2013) 0.82
The efficiency of targeted intervention in limiting the spread of HIV and Hepatitis C Virus among injecting drug users. J Theor Biol (2013) 0.81
Effects of population based screening for Chlamydia infections in the Netherlands limited by declining participation rates. PLoS One (2013) 0.80
Assessing interventions to reduce the risk of Campylobacter prevalence in broilers. Risk Anal (2007) 0.80
Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status. AIDS (2014) 0.80
Choosing pandemic parameters for pandemic preparedness planning: a comparison of pandemic scenarios prior to and following the influenza A(H1N1) 2009 pandemic. Health Policy (2012) 0.79
Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future. Inflamm Bowel Dis (2014) 0.79
Timeliness of contact tracing among flight passengers for influenza A/H1N1 2009. BMC Infect Dis (2011) 0.78
Self-reported Health Care Utilization of Patients with Inflammatory Bowel Disease Correlates Perfectly with Medical Records. Inflamm Bowel Dis (2016) 0.77
Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections. J Natl Cancer Inst (2012) 0.77
Treatment as prevention among injecting drug users; extrapolating from the Amsterdam cohort study. AIDS (2014) 0.77
[Surveillance]. Tijdschr Diergeneeskd (2010) 0.75
[Syndromic surveillance: a finger on the pulse of public health]. Ned Tijdschr Geneeskd (2014) 0.75
[Disease notification]. Tijdschr Diergeneeskd (2006) 0.75
Spatial Prediction of Coxiella burnetii Outbreak Exposure via Notified Case Counts in a Dose-Response Model. Epidemiology (2017) 0.75
Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease: A Comparison of Tools. Inflamm Bowel Dis (2016) 0.75
[Surveillance]. Tijdschr Diergeneeskd (2011) 0.75
[Noticed: outbreaks of infection]. Tijdschr Diergeneeskd (2006) 0.75
Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 0.75
[The evaluation process of public health action: the challenge of epidemiology]. Ig Sanita Pubbl (2004) 0.75
[Survey of the Council of Residents of the Italian Society of Hygiene (SItI) on the smoking habits of physicians training in Hygiene and Preventive Medicine.]. Ig Sanita Pubbl (2007) 0.75
[Observed]. Tijdschr Diergeneeskd (2006) 0.75